Health TrialsbyHealthPanel

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan

ConditionProteinuria
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRESnTEC, Institute of Research

About this trial

Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients of both genders with ≥18 years of age.

Presence of proteinuria/albuminuria at time of screening.

Creatinine clearance of 30 mL/min or higher.

Disqualifiers

A systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher.

Presence of a second primary renal disease in addition to diabetic nephropathy.

Patients with type 1 diabetes.

A history of a cardiovascular or cerebrovascular event within 3 months before inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Losartan

    Drug

    Patients will receives Losartan (LS) 50 mg per day.

  • Losartan + Hydrochlorothiazide

    Drug

    Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.

Treatment groups

234 Participants
are divided into 2 treatment groups
Group A: Losartan groupExperimental treatment 1 intervention
Group B: Losartan + HydrochlorothiazideExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Reduction of proteinuria

Efficacy will be labeled yes if reduction of proteinuria/albuminuria from the value before commencing treatment will be observed.

Time frame
4 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

RESnTEC, Institute of Research

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: